Portola leads with $60M round

CompanyAmount/RoundLead InvestorsDescription
Portola Pharmaceuticals
South San Francisco
$60M
FThird
D.E. Shaw group, Adage Capital Management, BBT Capital Management/Apothecary Capital, Janus Capital Group and PAC-LINK

Most of the funding will be used to advance Portola's lead drug betrixaban.

Light Sciences Oncology
Bellevue, WA
$40.1
Third
Unnamed

The funding will be used to advance its work on light infusion therapies.

Dicerna Pharmaceuticals
Cambridge, MA
$8.4M
First
Abingworth, Oxford Bioscience Partners and Skyline Ventures

Dicerna Pharmaceuticals is an RNA interference company.

Portola leads with $60M round

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.